Your browser doesn't support javascript.
loading
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement / 대한내과학회지
Korean Journal of Medicine ; : 485-494, 2019.
Article in Ko | WPRIM | ID: wpr-938598
Responsible library: WPRO
ABSTRACT
Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.
Full text: 1 Index: WPRIM Language: Ko Journal: Korean Journal of Medicine Year: 2019 Type: Article
Full text: 1 Index: WPRIM Language: Ko Journal: Korean Journal of Medicine Year: 2019 Type: Article